Hematologic Cancers Archives - Page 338 of 352

ASH 2012

ASH: Pomalidomide + Low-Dose Dexamethasone Improves PFS, OS in Relapsed/Refractory Multiple Myeloma

By

Debra Hughes, MS

December 11, 2012

Pomalidomide plus low-dose dexamethasone significantly improved progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory multiple myeloma vs high-dose dexamethasone alone and “should be considered as a new treatment option for these patients” who have exhausted lenalidomide and bortezomib, a study presented during the 54th American Society of Hematology Annual Meeting and Exposition recommended.

ASH 2012

ASH: Significantly Improved Survival Seen in Hairy Cell Leukemia

By

Debra Hughes, MS

December 9, 2012

Survival among patients with hairy cell leukemia has improved significantly over the past three decades, according to a study reported during the 54th American Society of Hematology Annual Meeting and Exposition.

ASH 2012

ASH: CLL Patients Ineligible for Fludarabine May Benefit from Rituximab-Bendamustine

By

Bryant Furlow

December 9, 2012

Rituximab-bendamustine showed significantly higher rates of complete response vs rituximab-chlorambucil in patients with chronic lymphocytic leukemia, according to interim results of the phase 3b study presented during the 54th American Society of Hematology Annual Meeting and Exposition.

ASH 2012

ASH: New Scoring System Predicts Survival of Unclassifiable Cases of MDS/MPN

By

Bryant Furlow

December 8, 2012

The first scoring system devised specifically for patients with unclassifiable cases of myelodysplastic syndrome and MDS/myeloproliferative neoplasms has identified several factors helpful in predicting survival outcomes, according to a study presented during the 54th American Society of Hematology Annual Meeting and Exposition.

Hematologic Cancers

Long-Term NHL Survivors with Comorbidity, Symptom Burden, Need Supportive Services

By

Debra Hughes, MS

December 4, 2012

The presence of comorbidity or symptom burden in long-term survivors of non-Hodgkin lymphoma should alert the clinician to a potential need for supportive services.

Hematologic Cancers

Ponatinib Highly Active in Patients with Ph-Positive Leukemias Refractory to TKIs

By

Debra Hughes, MS

November 29, 2012

Once-daily ponatinib, a pan-BCR-ABL inhibitor, was “highly active” in heavily pretreated patients with Philadelphia chromosome-positive leukemias resistant to tyrosine kinase inhibitors.

Hematologic Cancers

FDA Grants Orphan Drug Status to Adcetris for Mycosis Fungoides

November 26, 2012

Seattle Genetics announced that Adcetris (brentuximab vedotin) has been granted orphan drug designation by the FDA for the treatment of mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma (CTCL).

Hematologic Cancers

DR-COP + HAART Regimen Active, Tolerable, in AIDS-Related Lymphoma

By

Debra Hughes, MS

November 22, 2012

Profound immunodeficiency and high HIV-1 viral load in patients with AIDS-related lymphoma “do not preclude attainment of complete response.

Hematologic Cancers

High-Dose VSLI Monotherapy Provides Durable Responses in Ph-Negative ALL

By

Debra Hughes, MS

November 20, 2012

Use of high-dose vincristine sulfate liposome injection monotherapy in patients with advanced Philadelphia chromosome-negative acute lymphoblastic leukemia resulted in “meaningful clinical outcomes” that included durable responses and bridging to hematopoietic cell transplantation.

More Intensive Chemo Ups Survival in Ewing Sarcoma

Hematologic Cancers

Bone Marrow Biopsy Adds Little to PET/CT Staging of Hodgkin’s

November 15, 2012

Absence of positive bone marrow biopsy for patients with PET/CT-assessed stage I, II disease.

Diagnosis & Disease Information

ASH: Pomalidomide + Low-Dose Dexamethasone Improves PFS, OS in Relapsed/Refractory Multiple Myeloma

ASH: Significantly Improved Survival Seen in Hairy Cell Leukemia

ASH: CLL Patients Ineligible for Fludarabine May Benefit from Rituximab-Bendamustine

ASH: New Scoring System Predicts Survival of Unclassifiable Cases of MDS/MPN

Long-Term NHL Survivors with Comorbidity, Symptom Burden, Need Supportive Services

Ponatinib Highly Active in Patients with Ph-Positive Leukemias Refractory to TKIs

FDA Grants Orphan Drug Status to Adcetris for Mycosis Fungoides

DR-COP + HAART Regimen Active, Tolerable, in AIDS-Related Lymphoma

High-Dose VSLI Monotherapy Provides Durable Responses in Ph-Negative ALL

Bone Marrow Biopsy Adds Little to PET/CT Staging of Hodgkin’s

Adding Gemtuzumab Ozogamicin to Induction Therapy Reduces AML Relapse Rates in Older Patients